Revenue generation remains statistically irrelevant, with the company reporting zero revenue in 2026Q1 and failing to establish a sustainable path toward profitability.
Alaunos Therapeutics, Inc. (TCRT) annual income statement — 25-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 |
|---|
| Sales/Revenue | 3K | 5K | 10K | 5K | 2.92M | 398K | 0 | 0 | 146K | 6.39M | 6.86M | 4.33M | 1.37M | 800K | 800K | 667K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.57K | 1.73K |
| Revenue Growth % | -50% | -50% | 100% | -99.83% | 634.17% | - | - | -100% | -97.71% | -6.88% | 58.38% | 215.51% | 71.63% | 0% | 19.94% | - | - | - | - | - | - | - | - | -100% | 48.9% | - |
| Cost of Goods Sold | 847K | 1.36M | 362K | 4.8M | 22.52M | 47.27M | 1.13M | 629K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | 27260% | 3620% | 96060% | 770.64% | 11878.14% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -844K | -1.36M | -352K | -4.8M | -19.6M | -46.88M | -1.13M | -629K | 146K | 6.39M | 6.86M | 4.33M | 1.37M | 800K | 800K | 667K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.57K | 1.73K |
| Gross Margin % | -28133.33% | -27160% | -3520% | -95960% | -670.64% | -11778.14% | - | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | - | - | - | - | - | - | - | - | 100% | 100% |
| Gross Profit Growth % | - | -285.8% | 92.66% | 75.52% | 58.2% | -4055.76% | -79.33% | -530.82% | -97.71% | -6.88% | 58.38% | 215.51% | 71.63% | 0% | 19.94% | - | - | - | - | - | - | - | - | -100% | 48.9% | - |
| Operating Expenses | 3.21M | 2.87M | 4.46M | 29.47M | 15.51M | 30.67M | 79.23M | 57.23M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| OpEx % of Revenue | - | 57340% | 44600% | 589380% | 530.77% | 7706.53% | - | - | 37021.92% | 937.27% | 2509.37% | 2872.39% | 3268.17% | 7314.13% | 12871.13% | 10804.65% | - | - | - | - | - | - | - | - | 1654.12% | 4302.49% |
| Selling, General & Admin | 2.42M | 2.87M | 4.46M | 12.22M | 13.14M | 26.27M | 26.54M | 18.9M | 19.92M | 14.8M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0 | 120 |
| SG&A % of Revenue | - | 57340% | 44600% | 244380% | 449.76% | 6601.76% | - | - | 13642.47% | 231.62% | 209.55% | 407.36% | 886.09% | 1957.63% | 2440.38% | 2246.48% | - | - | - | - | - | - | - | - | - | 6.95% |
| Research & Development | 1.65M | 1.36M | 362K | 16.28M | 25.02M | 49.64M | 52.7M | 38.33M | 34.13M | 45.08M | 157.79M | 106.78M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 27260% | 3620% | 325580% | 856.19% | 12473.12% | - | - | 23379.45% | 705.65% | 2299.83% | 2465.03% | 2382.08% | 5356.5% | 10430.75% | 8558.17% | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -847K | -1.36M | -362K | 971K | -22.65M | -45.25M | 0 | 0 | 0 | 465K | 134K | 12K | -5K | -579K | -13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 486 | 42.51K | 74.14K |
| Operating Income | -4.06M | -4.22M | -4.81M | -34.27M | -35.1M | -77.55M | -80.36M | -57.86M | -53.91M | -53.49M | -165.31M | -120.1M | -43.5M | -57.71M | -102.17M | -71.4M | -24.55M | -12.12M | -25.62M | -28.57M | -19.11M | -9.79M | -39.17K | -35.84K | -39.94K | -72.53K |
| Operating Margin % | -135266.67% | -84500% | -48120% | -685340% | -1201.4% | -19484.67% | - | - | -36921.92% | -837.27% | -2409.37% | -2772.39% | -3168.17% | -7214.13% | -12771.13% | -10704.65% | - | - | - | - | - | - | - | - | -1554.12% | -4202.49% |
| Operating Income Growth % | - | 12.2% | 85.96% | 2.39% | 54.73% | 3.5% | -38.89% | -7.33% | -0.77% | 67.64% | -37.64% | -176.1% | 24.63% | 43.51% | -43.09% | -190.88% | -102.47% | 52.68% | 10.33% | -49.49% | -95.27% | -24889.54% | -9.27% | 10.26% | 44.94% | - |
| EBITDA | -4.01M | -4.22M | -4.81M | -31.95M | -32.35M | -74.95M | -79.23M | -57.23M | -53.33M | -53.12M | -165.02M | -119.74M | -43.04M | -56.98M | -101.51M | -71.13M | -24.36M | -11.79M | -25.23M | -28.14M | -18.94M | -9.69M | -5.65M | -35.36K | -39.14K | -71.78K |
| EBITDA Margin % | -133533.33% | -84360% | -48100% | -639040% | -1106.98% | -18832.16% | - | - | -36528.08% | -831.49% | -2405.14% | -2764.15% | -3134.52% | -7121.88% | -12688.88% | -10664.47% | - | - | - | - | - | - | - | - | -1523.03% | -4159.04% |
| EBITDA Growth % | -0.29% | 12.31% | 84.95% | 1.22% | 56.84% | 5.4% | -38.45% | -7.31% | -0.39% | 67.81% | -37.81% | -178.23% | 24.46% | 43.87% | -42.71% | -192.03% | -106.55% | 53.26% | 10.33% | -48.58% | -95.51% | -71.34% | -15889.77% | 9.67% | 45.47% | - |
| D&A (Non-Cash Add-back) | 24K | 7K | 2K | 2.31M | 2.76M | 2.6M | 1.13M | 629K | 575K | 369K | 290K | 357K | 462K | 738K | 658K | 268K | 188K | 330K | 388K | 433.35K | 173.92K | 101.23K | 0 | 486 | 799 | 750 |
| EBIT | -4.01M | -4.18M | -4.68M | -33.22M | -34.58M | -77.56M | -79.98M | -117.8M | -53.91M | -53.49M | -165.31M | -120.1M | -43.5M | -57.71M | -102.17M | -71.4M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -5.69M | -35.84K | -39.94K | -72.53K |
| Net Interest Income | 0 | 0 | 0 | -1.92M | -3.15M | -1.19M | 0 | 0 | 0 | -830K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 388K | 1.96M | 1.25M | 270.48K | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 1.92M | 3.15M | 1.19M | 0 | 0 | 0 | 830K | 0 | 0 | 0 | 0 | 0 | 0 | 8.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 48K | 49K | 133K | -873K | -2.63M | -1.2M | 385K | -59.94M | 789K | -830K | 10K | 12K | 11.72M | 606K | 6.04M | 7.62M | -8.12M | 4.47M | 388K | 1.96M | 1.25M | 270.48K | 0 | 0 | 0 | 0 |
| Pretax Income | -4.01M | -4.18M | -4.68M | -35.14M | -37.73M | -78.75M | -79.98M | -117.8M | -53.12M | -54.32M | -165.3M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | 0 | -17.86M | 0 | -39.17K | -35.84K | -39.94K | -72.53K |
| Pretax Margin % | -133666.67% | -83520% | -46790% | -702800% | -1291.24% | -19786.68% | - | - | -36381.51% | -850.26% | -2409.23% | -2772.11% | -2314.71% | -7138.38% | -12016.5% | -9561.92% | - | - | - | - | - | - | - | - | -1554.12% | -4202.49% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 114K | -12K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.96M | 0 | -270.48K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.07% | 0.01% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | - | 0% | - | 0% | 0% | 0% | 0% |
| Net Income | -4.01M | -4.18M | -4.68M | -35.14M | -37.73M | -78.75M | -79.98M | -117.8M | -53.12M | -54.32M | -165.3M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.53K |
| Net Margin % | -133666.67% | -83520% | -46790% | -702800% | -1291.24% | -19786.68% | - | - | -36381.51% | -850.26% | -2409.23% | -2772.11% | -2314.71% | -7138.38% | -12016.5% | -9561.92% | - | - | - | - | - | - | - | - | -1554.12% | -4202.49% |
| Net Income Growth % | -0.43% | 10.75% | 86.68% | 6.86% | 52.09% | 1.53% | 32.11% | -121.77% | 2.22% | 67.14% | -37.65% | -277.86% | 44.35% | 40.6% | -50.73% | -95.22% | -327.11% | 69.68% | 5.18% | -49.01% | -87.63% | -24198.94% | -9.27% | 10.26% | 44.94% | - |
| Net Income (Continuing) | -4.01M | -4.18M | -4.68M | -35.14M | -37.73M | -78.75M | -79.98M | -117.8M | -53.12M | -54.32M | -165.3M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.53K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.65 | -2.20 | -2.92 | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.44 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| EPS Growth % | 20.73% | 24.66% | 86.71% | 15.4% | 51.73% | 4.64% | 64.49% | -186.62% | 6.82% | 68.71% | -32.39% | -204.69% | 52.7% | 45.71% | -26.66% | -36.07% | -114.54% | 72.15% | 15.9% | 0.53% | 18.94% | -566.4% | -115.4% | 31.5% | 44.94% | - |
| EPS (Basic) | - | -2.20 | -2.92 | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.52 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| Diluted Shares Outstanding | 2.43M | 1.95M | 1.6M | 1.6M | 1.45M | 1.43M | 1.4M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.2K | 572.95K | 523.64K | 440.02K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993 | 1.96K | 1.49K | 1.49K |
| Basic Shares Outstanding | 2.43M | 1.95M | 1.6M | 1.6M | 1.45M | 1.43M | 1.4M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.2K | 572.95K | 523.64K | 440.02K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993 | 1.96K | 1.49K | 1.49K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying TCRT stock.
For fiscal year 2025, Alaunos Therapeutics, Inc. (TCRT) reported total revenue of $0.0M. This represents a 189.7% increase compared to $0.0M in 2001.
Alaunos Therapeutics, Inc. (TCRT) reported a net loss of $4.2M for the fiscal year ending 2025.
Alaunos Therapeutics, Inc. (TCRT) reported an operating income of $-4.2M, resulting in an operating profit margin of -84500.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Alaunos Therapeutics, Inc. (TCRT) generated $-1.4M in gross profit for the year, representing a gross profit margin of -27160.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Imminent liquidity insolvency risk
Metrics are mathematically derived from official filings.
Revenue Generation Remains Statistically Irrelevant
As indicated by the most recent quarterly filings, Alaunos Therapeutics reported revenue of zero, confirming that the company lacks a functional commercial engine and remains entirely dependent on non-recurring, nominal licensing inflows that fail to establish any meaningful growth trajectory for the business.
The absence of consistent top-line growth suggests that the company's TCR-T platform has yet to achieve any commercial validation or meaningful partnership milestones. Investors should view the reported revenue figures as noise rather than indicators of operational progress, as the firm functions more as a research entity than a commercial enterprise.
Expense Discipline Driven by Necessity
Based on the provided income statement data, the company has attempted to curb its cash burn by reducing quarterly R&D and SG&A expenditures, yet these efforts appear to be reactive measures to preserve a dwindling cash runway rather than evidence of sustainable operational efficiency.
The reduction in operating expenses reflects the cessation of clinical trial activities rather than a strategic optimization of the cost structure. This contraction in spending may further impair the company's ability to maintain its intellectual property or clinical readiness, potentially diminishing the value of its core assets.
Distorted Earnings Mask Structural Deficits
According to historical financial statements, the company's net losses are consistently exacerbated by high stock-based compensation and significant R&D overhead, which together render the reported EPS figures largely reflective of a distressed entity rather than a business with a viable path to profitability.
The persistent reliance on stock-based compensation during periods of clinical stagnation suggests a misalignment between executive incentives and shareholder outcomes. Analysts should monitor the impact of these non-cash charges on the company's remaining liquidity, as they represent a continued drain on the firm's limited resources.
Liquidation Risk Outweighs Platform Potential
While some market participants may argue that the Sleeping Beauty transposon system holds latent value, the company's reported financial data suggests that the firm is rapidly approaching a terminal liquidity event that may preclude any meaningful monetization of its intellectual property assets.
The high probability of a going-concern qualification suggests that the company's liabilities may soon exceed its realizable asset value. Investors should be wary of the assumption that the IP library can be easily sold or licensed, as the current financial distress likely weakens the company's negotiating position with potential acquirers.